The rise of Viagra initially sparked a period of growth for pharma, nevertheless recent developments present a complicated outlook for investors. Lower-cost alternatives are eroding revenue, and ongoing legal battles add further risk to the landscape. While specific companies might still see gains from related offerings, the broader direction su… Read More